8-K: Lifeward Forges Strategic Alliance with Oramed, Diversifies into Biotech

Lifeward Ltd. announced a transformative strategic partnership with Oramed Pharmaceuticals, integrating Oramed's oral drug delivery technology and securing up to $47 million in capital.

Summary

• Lifeward Ltd. (LFWD) is acquiring Oratech Pharma, Inc., a wholly-owned subsidiary of Oramed Pharmaceuticals Inc. (ORMP), which holds Oramed's Protein Oral Delivery (POD) technology.
• In exchange, Lifeward will issue Oramed ordinary shares and pre-funded warrants representing 49.99% of Lifeward's fully diluted equity capitalization, with ordinary shares not exceeding 45.00% post-closing.
• An additional $10 million in senior secured convertible notes (Initial Notes) and accompanying warrants will be issued to Oramed and other investors.
• A second tranche of $10 million in senior secured convertible notes (Second Notes) and warrants is contingent on Lifeward achieving a 150% increase in ReWalk Unit Sales (USD) relative to the trailing twelve-month period preceding the Additional Closing Date, or its share price reaching $1.15 for 10 consecutive trading days prior to the Additional Closing Date.
• The convertible notes carry an 8.0% annual interest rate, increasing to 15.0% upon default, with a 3-year maturity. Interest is payable semi-annually, commencing December 31, 2026, and can be paid in cash or added to principal.
• Lifeward will pay Oramed a 4% revenue share on net sales of its ReWalk Personal Exoskeleton products and related extended warranties for up to 10 years, or until Oramed receives an aggregate of $20 million (plus 2X any new Oramed investment, max $40M), or Lifeward's market capitalization reaches $200 million.
• Oramed will retain responsibility for managing and funding the clinical development of the POD platform, including a planned 60-patient U.S.-based clinical trial for ORMD-0801 (oral insulin capsule).
• Lifeward's officers and directors, along with Oramed, will be subject to a 120-day lock-up period post-closing for certain securities.
• The transaction is subject to Lifeward shareholder approval and other customary closing conditions.

Sentiment

Score: 8

Explanation: The strategic partnership and significant capital infusion provide Lifeward with a strong financial foundation and a clear path to diversification and potential long-term growth in the biotech sector, despite the inherent risks of clinical development and shareholder dilution.

Positives

• Secures up to $47 million in strategic capital, providing a path to profitability for Lifeward's existing MedTech products.
• Diversifies Lifeward's portfolio by integrating Oramed's clinical-stage Protein Oral Delivery (POD) technology, adding long-term biotech upside potential.
• POD technology targets a large global injectable drugs market ($600+ billion), including diabetes ($80+ billion annually).
• Oramed will manage and fund the POD clinical program, allowing Lifeward to focus on its core MedTech business and cash generation.
• Lifeward CEO Mark Grant brings extensive and relevant experience in the diabetes industry, having held senior leadership roles at Medtronic and Bristol Myers Squibb.
• ORMD-0801 (oral insulin capsule) has successfully completed a Phase 2b trial, meeting its primary endpoint with a statistically significant reduction in HbA1c.
• The revenue sharing payments from ReWalk products provide Oramed with a royalty stream, aligning interests.

Negatives

• Significant potential dilution for existing Lifeward shareholders, as Oramed will acquire up to 49.99% of Lifeward's fully diluted equity.
• The transaction is contingent on Lifeward shareholder approval, which introduces uncertainty.
• The second tranche of $10 million in convertible notes is subject to performance milestones (ReWalk sales increase or share price target), which may not be met.
• The Phase 3 study for ORMD-0801 did not meet its primary endpoint, indicating potential challenges in clinical development, despite encouraging subgroup data.
• The 8.0% annual interest rate on convertible notes increases to 15.0% upon default, posing a financial risk.
• A 120-day lock-up period for officers, directors, and Oramed could limit liquidity for these parties.

Risks

• Failure to obtain Lifeward shareholder approval for the transaction.
• Inability to meet the conditions for the second $10 million convertible note tranche (150% ReWalk Unit Sales increase or $1.15 share price for 10 consecutive trading days).
• Clinical development risks associated with the POD technology and ORMD-0801, given the prior Phase 3 study not meeting its primary endpoint.
• Potential for significant dilution of existing Lifeward shareholders due to the issuance of new shares and warrants to Oramed and other investors.
• The 8.0% annual interest on convertible notes, increasing to 15.0% upon default, could strain Lifeward's finances.
• Maintaining Nasdaq listing standards, potentially requiring a reverse share split.
• Uncertainties associated with future clinical trials, product development, and FDA regulatory approval processes for new biotech products.
• Ability to maintain and grow reputation and market acceptance of existing and new products.
• Ability to achieve reimbursement from third-party payors for products.
• Reliance on third-party suppliers and contract manufacturers.
• Compliance with medical device reporting regulations and potential impact of adverse events.
• Maintaining adequate protection of intellectual property and avoiding infringement.
• Risk of cybersecurity attacks or breaches of IT systems.
• Potential for unexpected costs, charges, or expenses resulting from the Proposed Transactions.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Proposed Transactions.
• Legislative, regulatory, political, and economic developments impacting the MedTech and Biotech industries.

Future Outlook

Lifeward aims to operate as a disciplined biomedical portfolio company, focusing on achieving sustainable profitability from existing FDA-approved MedTech products (ReWalk and AlterG), selectively deploying capital towards assets with defined milestones and risk-adjusted returns, and building a balanced, diversified biomedical portfolio combining near-term revenue with longer-term biotech innovation. Oramed plans to initiate a 60-patient U.S.-based clinical trial for ORMD-0801.

Management Comments

• "Oramed is the ideal strategic partner for Lifeward at this pivotal moment in our company's evolution. This transaction, if approved, is expected to provide us with the financial resources to reach profitability with our proven ReWalk and AlterG product lines while simultaneously unlocking significant growth opportunities through the integration of Oramed's POD technology. We see tremendous potential to advance the oral insulin program as we build a truly diversified biomedical innovation company." Mark Grant, President and CEO of Lifeward.
• "We are currently evaluating several other opportunities to expand our portfolio as we optimize revenues and are on a clear path to cash flow positive." Mark Grant, President and CEO of Lifeward.
• "This transaction represents an important strategic milestone for Oramed. By transferring our POD technology to Lifeward with an ownership stake, Oramed shareholders retain substantial exposure to the oral delivery platform while simultaneously gaining meaningful participation in a proven revenue-generating medical robotics business and royalty streams. With Mark Grant's extensive diabetes industry experience at the helm, we are confident in Lifeward's ability to advance both the medical robotics and oral insulin platforms." Nadav Kidron, CEO of Oramed.

Industry Context

This transaction positions Lifeward as a diversified biomedical innovation company, expanding beyond its core MedTech (medical robotics like ReWalk and AlterG) into the high-growth Biotech sector, specifically targeting the large injectable drug delivery market with Oramed's oral protein delivery technology. This move aligns with a broader industry trend of companies seeking diversification and leveraging platform technologies to address significant unmet medical needs, such as oral alternatives for injectable therapies in chronic diseases like diabetes. The focus on achieving profitability from existing products while investing in long-term biotech innovation reflects a strategic approach to balance immediate financial stability with future growth opportunities in a competitive healthcare landscape.

Comparison to Industry Standards

• The acquisition of POD technology positions Lifeward to compete in the oral drug delivery market, which aims to convert injectable biological therapies into oral medications, a significant innovation compared to traditional injection methods.
• ORMD-0801, the oral insulin capsule, aims to create a new paradigm in type 2 diabetes treatment by enabling earlier intervention, potentially differentiating it from existing insulin therapies that are primarily injectable.
• The target market for POD technology, the $634 billion global injectable drug delivery market, and the $80+ billion annual diabetes market (including $19 billion insulin and $52 billion GLP-1 analogs in 2024), indicates a substantial opportunity for a successful oral delivery platform.
• Lifeward's CEO, Mark Grant, brings relevant industry experience from Medtronic (diabetes business exceeding $1.5 billion in annual revenue) and Bristol Myers Squibb, which is a strong asset for navigating the diabetes and biotech markets.

Management Changes

Corporate Governance

Legal Proceedings

• No new material legal proceedings are mentioned. The filing states that there are no pending or threatened legal proceedings that would challenge the transaction or have a Material Adverse Effect.

Related Party Transactions

• Lifeward is acquiring Oratech Pharma, Inc., a wholly-owned subsidiary of Oramed Pharmaceuticals Inc. (Oramed is the seller).
• Lifeward will issue ordinary shares and pre-funded warrants to Oramed.
• Lifeward will issue transaction warrants to Oramed.
• Lifeward will pay quarterly revenue sharing payments to Oramed based on ReWalk product sales.
• Lifeward entered into a Securities Purchase Agreement with Oramed and certain other investors for convertible notes and warrants. Oramed is also acting as collateral agent for the purchasers.
• Oramed will manage and fund the clinical development of the POD platform under a Clinical Trial Management Agreement.
• Oramed will designate two members to Lifeward's Board of Directors upon closing.
• Lifeward's officers and directors, and Oramed, are subject to a 120-day lock-up agreement.

Stakeholder Impact

• Shareholders (Lifeward): Potential for significant dilution due to the issuance of new equity to Oramed and other investors. However, the capital infusion and diversification into biotech could offer long-term growth and value creation. Shareholder approval is required.
• Shareholders (Oramed): Retain substantial exposure to the oral delivery platform through equity ownership in Lifeward and gain participation in a revenue-generating medical robotics business and royalty streams.
• Employees (Lifeward/Oratech): Integration of Oratech's POD technology and clinical programs may lead to new roles or shifts in focus, particularly in R&D. Lifeward's path to profitability could enhance job security.
• Customers (Lifeward): Continued focus on existing FDA-approved MedTech products (ReWalk, AlterG) with potential for selective investment in high-value innovation, potentially leading to improved or new products.
• Creditors (Lifeward): The capital raise through senior secured convertible notes provides additional funding, but also introduces new debt obligations with an 8.0% interest rate (15.0% upon default). The notes are secured by collateral.
• Regulatory Authorities: The transaction involves various regulatory approvals and filings, including with Nasdaq and the SEC, and compliance with Israeli law for board composition.

Next Steps

• Obtain Lifeward shareholder approval for the transaction.
• Lifeward to issue ordinary shares, pre-funded warrants, and transaction warrants to Oramed.
• Lifeward to issue initial senior secured convertible notes and accompanying warrants to Oramed and other investors.
• Lifeward to use commercially reasonable efforts to cause a registration statement (Form S-1 or S-3) to register the issued shares to be declared effective by the SEC within 75 days (or 105 days if SEC reviews) following closing.
• Lifeward to file a registration statement for shares underlying the Notes and Warrants within 30 days of the Initial Note closing, aiming for effectiveness within 45 days (or 75 days if SEC reviews) following such closing.
• Oramed to manage and fund the anticipated clinical program for the POD platform, including a planned 60-patient U.S.-based clinical trial for ORMD-0801.
• Lifeward to evaluate other opportunities to expand its portfolio.
• Lifeward to maintain Nasdaq listing.
• Lifeward to pay quarterly revenue sharing payments to Oramed based on ReWalk product sales.

Key Dates

Recommendation

The strategic partnership with Oramed and the associated capital raise provide Lifeward with a much-needed financial runway and a compelling diversification into the high-potential biotech sector. The acquisition of the POD technology and the oral insulin program (ORMD-0801) offers significant long-term upside, especially given the vast market for injectable drugs. However, the substantial potential dilution for existing shareholders, the contingency of shareholder approval, and the inherent risks associated with clinical-stage biotech development (as evidenced by the prior Phase 3 outcome for ORMD-0801) introduce considerable uncertainty. While the financial stability and strategic direction are positive, the execution risks and the dilutive impact warrant a cautious 'hold' recommendation until further clarity emerges on clinical trial progress, market adoption of the new technology, and the actual financial performance post-integration. Investors should monitor the shareholder vote, the progress of the ORMD-0801 clinical trial, and Lifeward's ability to achieve its profitability and growth targets.

Keywords

Lifeward, Oramed, Oratech, Strategic Partnership, Biomedical Innovation, MedTech, Biotech, Oral Drug Delivery, POD Technology, ORMD-0801, Oral Insulin, Convertible Notes, Warrants, Equity Investment, ReWalk Exoskeleton, AlterG Anti-Gravity System, Clinical Trials, Shareholder Approval, Nasdaq Listing, Capital Raise, Diabetes Treatment, Medical Robotics